Navigation Links
Inovio Pharmaceuticals Reports 2011 Second Quarter Financial Results
Date:8/8/2011

http://ir.inovio.com/index.php?s=43&item=15">Phase II clinical trial for VGX-3100, which is assessing the vaccine in women with CIN 2/3 or CIN 3 cervical dysplasias, the stages of abnormal cells preceding cervical cancer. The company expects to enroll 148 patients in 25 study centers in the U.S., South Korea, South Africa, Australia, and Canada. Data is expected in the second half of 2013.

The University of Southampton, an Inovio collaborator, is enrolling patients in its Phase II clinical trial of its DNA vaccine to treat chronic myeloid leukemia and acute myeloid leukemia using Inovio's electroporation delivery system. Interim data is expected in 2012.

Another partner, ChronTech Pharma AB, is enrolling patients in its Phase IIb clinical study of its ChronVac-C® DNA vaccine for hepatitis C virus (HCV) delivered with Inovio's proprietary electroporation DNA vaccine delivery technology in combination with standard of care. Interim data is expected in 2012.

Inovio recently reported that significant T cell and antibody responses were generated in its proof-of-principle Phase I clinical study of VGX-3400X, its preventive H5N1 (avian) influenza SynCon® DNA vaccine delivered using intramuscular (IM) electroporation (EP). VGX-3400X/EP was found to be generally safe and well tolerated at all dose levels, with no vaccine-related serious adverse events. Reported adverse events and injection site reactions were mild to moderate and required no treatment. Three of 27 subjects (11%) showed HI titers (an indicator of protection in humans) greater than 1:40 against the Vietnam (A/H5N1/1203/04) strain. Two of these three subjects also demonstrated greater than 1:40 titers against the Indonesia (A/H5N1/5/2005) strain, demonstrating cross-reactive responses. '/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
2. Inovio Pharmaceuticals Announces Transition of Avtar Dhillon to Non-Executive Chairman of the Board
3. Inovio Pharmaceuticals to Present at Scientific & Industry Conferences
4. Inovio Pharmaceuticals Subsidiary, VGX Animal Health, to Present at VetHealth Global 2011, June 14-17, 2011
5. Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011
6. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
7. Inovio Pharmaceuticals to Present at Investor Conferences
8. Inovio Pharmaceuticals, Transgene and ChronTech Pharma to Collaborate on Heterologous Prime-Boost Therapeutic Vaccination Against Hepatitis C
9. OncoSec Medical Closes Purchase and License Agreement for Tumor Therapy Technology with Inovio Pharmaceuticals
10. Inovio Pharmaceuticals to Present at Scientific Conferences
11. Inovio Pharmaceuticals Receives U.S. DOD Small Business Innovation Research Grant for Multi-Vaccine DNA Delivery Device Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... -- Heska Corporation (Nasdaq: HSKA ) announces the ... Third Quarter 2014 Earnings Conference Call on the WebWhen:Wednesday, ... a.m. (EDT)Where: , www.heska.com (click on the ... of this website)How:Live over the Internet -- Simply log ... you may use the following teleconference access numbers:  Domestic: ...
(Date:10/25/2014)... Oct. 24, 2014   Metanome, Inc. , a ... services and data analysis, was the genomic sequencing provider ... Phase I/II clinical trial of SER 109, an Ecobiotic® ... Clostridium difficile infections (CDI). Metanome has ... R&D and clinical programs. Such genomic characterization has enabled ...
(Date:10/25/2014)... 2014 Best Practices designed the Medical ... a forum for sharing insights about the key ... mechanism for creating and sharing solutions through three ... from the Medical Affairs Consortium survey. ... the first roundtable of the 2014-2015 Medical Affairs ...
Breaking Medicine Technology:Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... , KINGWOOD, Texas , ... (Pink Sheets: IMAI.PK) www.imaiinc.com announced today that ... purchase a minority interest in Assured Pharmacy, Inc. (Pink ... that is focused on selling prescription medications in the ...
... , WEST PALM BEACH, Fla. ... 50+ who have hearing loss, the AARP Hearing Care program, provided by HearUSA ... part of a nationwide rollout. , While one in 10 Americans have hearing ... suffer from this life altering condition. According to the National Institutes of ...
Cached Medicine Technology:International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 2HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 3HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 4HearUSA Introduces AARP Hearing Care Program for Americans Aged 50-plus in Ohio Today 5
(Date:10/25/2014)... 24, 2014 (HealthDay News) -- October,s shorter, darker days ... affective disorder, according to an expert. People ... feel overly tired, lack motivation and even have trouble ... lead to suicide, said Dr. Angelos Halaris, a professor ... Loyola University Chicago Stitch School of Medicine. "Seasonal ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world ... face, it certainly can be difficult to choose the right ... favor by doing it the healthy way? Set aside the ... your body, exercise regularly, and choose foods with the most ... you need to exercise more and eat less. Despite the ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2
... Morphotek(R), Inc., a subsidiary of Eisai ... Food and Drug Administration (FDA) has agreed to and ... clinical trial evaluating farletuzumab (also known as MORAb-003) in ... agreement was made under the Special Protocol Assessment (SPA) ...
... WebMD Health Corp. (Nasdaq: WBMD ), the ... States, today announced a long-term strategic relationship with Boots ... in the United Kingdom, to jointly develop a consumer ... new joint offering will leverage WebMD,s online consumer health ...
... Issues Alert maintaining recommendation in support of LCA,s current ... LCA-Vision Inc. (Nasdaq: LCAV ) announces that ... affirming its recommendation that LCA-Vision stockholders vote ... reject all proposals, including the removal of the current ...
... March 23 Medical images are increasingly ... digitised medical images poses an immense challenge ... It is essential that image archive storage ... (PACS) vendors and image modality manufacturers become ...
... news is the best news that we have been waiting ... of the medication through Sinus Dynamics.WESTLAKE VILLAGE, Calif., March 23 ... have always asked if it would be better to have ... and penetrated into the sinuses. Now this fantastic news and ...
... States is in dire need of more physicians. But ... problem, the report points out that the issue cannot ... or expanding existing schools. For more than 30 ... qualified students, who show the commitment and determination to ...
Cached Medicine News:Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 2Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 3Health News:Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer 4Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 2Health News:RiskMetrics Affirms Recommendation that Stockholders Support LCA-Vision Board of Directors and Reject All Proposals by Dissident Joffe Group 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 2Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 3Health News:Europe Poised for Exponential Growth in the Digitised Medical Imaging Storage Space, Reveals Frost & Sullivan 4Health News:New Clinical Study News for Treatment of Sinusitis, Sinus Infection and Allergy Sufferers Now Have a New Effective Form of Relief through Sinus Dynamics 2Health News:Ross University School of Medicine Succeeds Where Others Fall Short, According to Standards Established in New Report 2Health News:Ross University School of Medicine Succeeds Where Others Fall Short, According to Standards Established in New Report 3
... The S7 with Discrete Technology Coronary ... unmatched scaffolding. Proprietary Secure Technology stent ... pillows that partially encapsulate the stent ... Technology is designed to minimize balloon ...
Unique Radial Tandem Architecture Stent Design for enhanced flexibility and force characteristics....
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
For support, strength and control in your interventions, the RunWay Guide Catheter's large lumen and high-performance design represents a new era in guide catheters....
Medicine Products: